SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1096)12/10/1998 11:38:00 AM
From: Anthony Wong  Respond to of 1580
 
Merck & Co. Cut to 'Accumulate' at Deutsche Bank Target $175

Princeton, New Jersey, Dec. 10 (Bloomberg Data) -- Merck & Co., Inc. (MRK US) was downgraded to ''accumulate'' from ''buy'' by analyst Mariola B. Haggar at Deutsche Bank Securities. The 12-month target price is $175.00 per share.



To: Anthony Wong who wrote (1096)12/10/1998 11:46:00 AM
From: Anthony Wong  Respond to of 1580
 
Merck & Co. Reiterated Short-Term 'Outperform' at Everen Targets $164 & $175

Princeton, New Jersey, Dec. 10 (Bloomberg Data) -- Merck & Co., Inc. (MRK US) was reiterated short-term ''outperform'' by analyst Jeffrey J. Kraws at Everen Securities. The long-term rating was reiterated ''outperform.'' The intermediate and long-term price targets are $164. and $175., respectively.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News